Oct 29, 2026 earnings call — KT-579 safety and KT-621 Phase IIb timing
Kymera reported robust IRF5 biomarker effects with KT-579 (up to 94% degradation) and expects KT-621 Phase IIb AD data by year-end.
Revenue $0.0B (est $0.0B) · EPS $-1.32 (est $-1.26)
Key quotes
"We expect that the remaining activities to close out this portion of the study will enable us as planned to share the KT-621 Phase IIb data by year-end."
"KT-579, which was well tolerated in this study, robustly degraded IRF5."
"We ended September with cash, cash equivalents and investments of approximately $1.6 million, providing a runway into 2029"
Analyst Q&A 22
Phase Ib goals and dosing
Q (Lut Ming Cheng · JPMorgan): Asked how Kymera defines success for the Phase Ib LUMORA trial, which doses might move forward given saturation at dose level 3, and whether patients can taper steroids.
A: The study aims to show the drug can modulate disease biology without ex vivo stimulation by demonstrating IRF5 relevance in lupus. They have multiple dose options since all doses showed more than 85% degradation and will pick the dose that best answers the study goals. The trial design will likely include tapering since taper is commonly incorporated in lupus studies.
"We'll be able to do that without having to artificially stimulate the pathway ex vivo" — Terence Rooney
IRF5 variability and tissue levels
Q (Thomas Smith · Leerink Partners): Asked about intrapatient variability in IRF5 degradation, any subjects missing the 80% threshold, differences between serum and skin, and how TLR7/8 class data affects their view.
A: They said degradation was robust and consistent with very small error bars and no outliers; skin versus blood differences were minimal though skin expression is very low. They view TLR7/8 inhibition data as confidence-building but note their mechanism extends beyond TLR7/8.
"Our degradation profile as now for -- this is the sixth program we show data for is always extremely robust and consistent." — Nello Mainolfi (CEO)
Market expansion for KT-621
Q (Derek Archila · Wells Fargo): Asked how an effective oral KT-621 could expand the atopic dermatitis market and whether it could similarly expand markets in asthma, COPD, and other diseases.
A: They said KT-621 could be the first effective oral for type 2 diseases and would treat comorbidities, expanding the pool of patients reluctant to use injectable biologics. They expect similar market expansion potential in other diseases dominated by injectables, like asthma and EoE, by bringing new patients into treatment.
"The opportunity here that we have with the potentially the first effective oral drug is to expand the market of patients that are sitting on the sidelines because they're not comfortable with the idea of taking an injectable biology." — Nello Mainolfi (CEO)
Other disease opportunities for KT-579
Q (Citi): Asked whether today's KT-579 data support development beyond lupus, such as in IBD, Sjogren's, or rheumatoid arthritis.
A: They noted genetic links between IRF5 overactivity and those diseases and that the three key pathways they measured map to mechanisms implicated in IBD, Sjogren's and RA. They plan LUMORA as one of multiple patient studies to explore broader opportunities.
"You can draw threads between each of those and rheumatoid arthritis and/or Sjogren's disease or IBD." — Terence Rooney
BROADEN-2 baseline characteristics
Q (Michael Ulz · Morgan Stanley): Asked for thoughts on baseline characteristics of BROADEN-2 and how that may affect cross-trial comparisons to dupilumab Phase III studies.
A: They declined to share baseline details now, saying they'll preserve patient characteristics until they report the data later this year. The only update given was that 98% of eligible patients enrolled into the open-label extension after the 16-week study.
"Of the eligible patients, 98% enrolled into the OLE." — Nello Mainolfi (CEO)
Reducing placebo response in AD trial
Q (Biren Amin · Piper Sandler): Asked what measures were used in BROADEN-2 to mitigate high placebo response historically seen in AD studies.
A: They prioritized quality over speed with careful site and investigator selection, control of prior and concomitant therapies, and novel measures to ensure true moderate-to-severe AD patients. Despite the tight criteria, the trial enrolled about two quarters early due to strong interest.
"Measures included careful site selection, careful investigator selection, control of factors that can sometimes drive placebo response rate like previous medications or concomitant therapies coming into the trial." — Terence Rooney
Subpopulation and biomarker data in BROADEN-2
Q (Alexander Thompson · Stifel): Asked what to expect beyond primary endpoints in BROADEN-2, specifically subpopulations like comorbid asthma and biomarker data.
A: They can't commit before seeing the data but intend the first disclosure to include all material safety and efficacy information. Additional scientific details may be preserved for later presentations or publications.
"The goal of the first disclosure is to ensure that we share all the data that we believe is material to obviously the company and to investors to assess the safety and efficacy profile of the drug." — Nello Mainolfi (CEO)
Extracellular degrader technologies
Q (Faisal Khurshid · Jefferies): Asked whether Kymera would explore extracellular degrader platforms or related modalities in the future.
A: They said their strengths are target selection, small-molecule ligands, heterobifunctional chemistry and oral degraders, so contiguous technologies like extracellular degraders are of interest. However, they view oral delivery as a key advantage and doubt they'd pursue injectable extracellular degraders because other technologies can handle extracellular targets more efficiently.
"Another thing that we're really good at is any type of heterobifunctional molecule chemistry." — Nello Mainolfi (CEO)
Phase III planning for KT-621
Q (Jeffrey Jones · Oppenheimer): Asked about updates to thinking on Phase III plans and additional indications for KT-621 beyond AD and asthma.
A: They plan to launch KT-621 in all relevant type 2 inflammation indications, prioritizing those with highest unmet need and opportunity for an oral drug. They will share a more comprehensive late development plan early next year after BROADEN-2 readout.
"Our goal is to launch KT-621 in all indications that we believe are relevant to type 2 inflammation." — Nello Mainolfi (CEO)
Interferon-high enrolment in lupus study
Q (Kevin Meli · RBC Capital): Asked whether the Phase Ib lupus study will enroll both interferon-high and interferon-low patients and whether later stages should focus on interferon-high.
A: They will enroll both interferon-high and low patients and consider it premature to restrict enrollment to a biomarker-driven subset. They want to learn from a broader, well-controlled lupus population because IRF5's mechanism extends beyond interferon inhibition.
"We will enroll both interferon-high and low patients." — Terence Rooney
Dosing flexibility and reversibility
Q (Wolfe): Asked whether the PD data suggest flexibility in dosing frequency or rapid reversibility if safety issues emerge.
A: They said when dosing stops the target returns to baseline in a few days and biomarker kinetics mirror degradation, noting drug half-lives are in hours. Thus they expect dosing can be adjusted and any pathway recovery would be relatively quick if needed.
"When you stop dosing, the degradation, obviously, the target comes back to baseline in a few days." — Nello Mainolfi (CEO)
Translating biomarkers and safety concerns
Q (Morgan Lamberti · Goldman Sachs): Asked how healthy volunteer biomarker reductions translate to lupus patients and whether >90% IRF5 degradation raises specific safety concerns.
A: They expect to see pathway changes in lupus patients and are confident full pathway blockade in ex vivo stimuli supports that, but patient stimuli may be less robust than ex vivo. Safety so far is encouraging with no infection signal in Phase I and preclinical work, and they will continue careful monitoring.
"On the safety side, we've been encouraged by the safety profile seen preclinically before this study and particularly encouraged by the preliminary safety data we've seen here in Phase I, including a lack of any signal with respect to infection." — Terence Rooney
Comparing KT-621 to dupilumab
Q (David Hoang · Deutsche Bank): Asked what ballpark to expect versus dupilumab for endpoints like EASI-75 and IGA 0/1, and whether KT-621 could outperform dupilumab at 16 weeks.
A: They said blocking IL-4/13 via STAT6 degrader seems to block downstream signaling similarly to biologics, but cross-trial comparisons are flawed and they won't give exact numbers. The priority is demonstrating safety, efficacy and tolerability for an exciting oral therapy rather than strict replication of dupilumab results.
"Cross-trial comparisons are technically not doable and they have an inherent flaw in the approach." — Nello Mainolfi (CEO)
Itch data and IL-31 reductions
Q (Tyler Van Buren · TD Cowen): Asked if itch data will be in the initial BROADEN-2 release and whether KT-621 might differentiate on itch given IL-31 reductions.
A: They will include itch, sleep and quality-of-life data in the disclosure because these matter to patients and they plan to share such measures. They were cautious about over-interpreting IL-31 blood reductions versus dupilumab and said better measurement could explain differences; full clarity will come when data are released.
"Yes. We plan to have itch data, of course, itch, sleep itch, quality of life." — Nello Mainolfi (CEO)
Exploratory endpoints in KT-579 lupus study
Q (Jeet Mukherjee · BTIG): Asked which exploratory clinical endpoints will be used in KT-579 Phase Ib and what would indicate clinical differentiation.
A: They will assess usual lupus clinical outcome measures including composites like SLEDAI and BILAG plus individual components, with biomarker data as the study's chief focus. The study is not powered for clinical endpoints; clinical measures are exploratory and will be interpreted cautiously given high placebo rates in lupus.
"We look at all of the usual lupus clinical outcome measures, including composites like SLEDAI and BILAG." — Terence Rooney
Dose-response across MAD cohorts
Q (Jasmine Fels · Barclays): Asked to characterize dose-response across MAD cohorts for ex vivo stimulation biomarkers and whether saturation at dose level 3 was seen.
A: They declined to disclose detailed dose-response on biomarkers to preserve competitive advantage and said they have a clear understanding of the dose needed based on degradation and biomarker changes. For now they will retain that information.
"So the reason why we're not sharing, let's call it, the dose response on biomarkers because I personally don't want to share what is the level of IRF5 degradation to that leads to the optimal biomarker changes that we're seeing." — Nello Mainolfi (CEO)
Signals to watch in other diseases
Q (Seamus Fernandez · Guggenheim): Asked what they'd look for from other disease states (e.g., Sjogren's) to link robust biomarker effects and opportunities beyond lupus.
A: They said Sjogren's is a strong potential indication due to unmet need, genetic links to IRF5, and its interferon-driven biology; B-cell therapies have shown efficacy there. They are encouraged and carefully considering Sjogren's as a target indication.
"I think Sjogren's is a really good indication for the target." — Terence Rooney
Conjunctivitis expectation and 2027 catalyst
Q (Tazeen Ahmad · BofA): Asked if absence of conjunctivitis would be meaningful and what Kymera sees as top 2027 catalysts.
A: They expect conjunctivitis mechanistically from IL-4/13 biology and would discuss reasons if it's absent, but they didn't commit further. The top 2027 catalyst they cited is the large asthma dataset that could enable multiple Phase III programs, with AD moved earlier to this year and asthma planned for next year.
"The next one, let's start with your second question. Obviously, we have big data with asthma, which will be a huge catalyst to initiate multiple Phase III programs in asthma and other respiratory indications." — Nello Mainolfi (CEO)
IAE breakouts and itch benchmark
Q (B. Riley): Asked whether BROADEN-2 reporting will use the same conjunctivitis/keratitis clusters as the dupilumab label for comparison, and how KT-621 compares to Nemlivo on itch.
A: They will present data so investors can assess efficacy and safety and make interpretable comparisons, but they can't say specifics until they see the data. They noted Nemlivo is not a highly active drug though it impacts itch via IL-31, and KT-621 also affects IL-31 downstream; definitive comparisons await the data.
"For sure, we will present the data in a way that, as I said earlier, everybody should be able to assess the efficacy and the safety of the drug as well as whether there has to be any comparator way of looking at also safety, we'll do it in the way that is interpretable." — Nello Mainolfi (CEO)
Skin as surrogate for tissue engagement
Q (Xiaochuan Dai · UBS): Asked how similar IRF reduction in skin and blood supports peripheral blood as a surrogate for engagement in disease tissues like lupus or IBD.
A: They use skin in healthy volunteers to derisk distribution beyond blood because skin is hard to degrade targets in; degrading in skin suggests good degradation elsewhere. They also have preclinical data showing consistent degradation in relevant tissues, so skin was an additional validation.
"If you degrade in skin, you're probably going to be fine for the rest of the body." — Nello Mainolfi (CEO)
Demand and enrollment differences in asthma
Q (Srikripa Devarakonda · Truist): Asked whether they see similar demand for the asthma program as AD, whether enrollment rates increased, and how predictive FEV1 is for exacerbation benefit.
A: They see similar enthusiasm for asthma as for AD, but asthma enrollment is slower due to stricter inclusion/exclusion criteria and higher screen failure rates. They did not comment here on how predictive FEV1 is for exacerbation benefit.
"The main difference is that in asthma, our inclusion/exclusion criteria are much more strict." — Nello Mainolfi (CEO)
R&D spend and runway into 2029
Q (Joseph Holden · Canaccord Genuity): Asked for guidance on expected R&D spending into 2027 given KT-579 Phase I and planned Phase III in AD.
A: They didn't give explicit guidance; instead they pointed to runway into 2029 and said operating expenses will increase gradually, accelerating as they start the Phase III AD study by mid-2027 and add team members. Those factors will drive cash use in 2027 and beyond.
"You should see, I would say, increases in operating expenses that are gradual but consistent to get you to the point that you're into 2029." — Bruce Jacobs (CFO)